Bio-Rad Laboratories, Inc.
BIO Healthcare Medical Devices
Bio-Rad Laboratories, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.6 billion, up 0.65% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS grew 19.0%, free cash flow fell 6.06% and total debt was flat, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
Follow BIO
Bio-Rad Laboratories, Inc. (BIO) EV/Sales
As of 16 October 2026, Bio-Rad Laboratories, Inc. (BIO) trades at a EV/Sales of 3.5×. Over the past ten years it has ranged from 1.4× (January 2015) to 8.1× (September 2021); the current reading is higher than 52% of that period. That is above the Medical Devices industry median of 2.2× and in line with the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 3.1× | (10.61%) |
| FY2024 | 3.4× | (0.03%) |
| FY2023 | 3.4× | (19.75%) |
| FY2022 | 4.3× | (42.34%) |
| FY2021 | 7.4× | 15.33% |
| FY2020 | 6.4× | 43.46% |
| FY2019 | 4.5× | 57.46% |
| FY2018 | 2.8× | (10.01%) |
| FY2017 | 3.2× | 31.50% |
| FY2016 | 2.4× | 31.63% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 2.9× | 4.00% |
| Mar 2026 | 2.8× | (9.94%) |
| Dec 2025 | 3.1× | 6.96% |
| Sep 2025 | 2.9× | 14.45% |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| SNN Smith & Nephew SNATS, Inc. compare | 1.5× |
| BRKR Bruker Corporation compare | 2.9× |
| PODD Insulet Corporation compare | 3.3× |
| GMED Globus Medical, Inc. compare | 3.4× |
| BIO Bio-Rad Laboratories, Inc. | 3.5× |
| BIO.B Bio-Rad Laboratories, Inc. compare | 3.6× |
| HAE Haemonetics Corporation compare | 4.7× |
| PEN Penumbra, Inc. compare | 8.0× |
| GKOS Glaukos Corporation compare | 15.9× |
| Medical Devices industry median | 2.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)